Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

CAMBRIDGE, Mass. & MONTREAL, April 25, 2025--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ...

All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff assistance will be immediately available when submitters need it. If you begin your ...

For more and to view the abstract, visit the AACR Annual Meeting website. As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) ( ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced that abstracts for multiple presentations have been accepted for the 2025 National Summit of the US Hereditary Angioedema ...

With the fall ACS national meeting right around the corner, the time has come to put your poster presentation together. While the abstract was submitted months ago, you were waiting to create the ...

Submissions that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA ...